Epitope-level precision is unlocking new frontiers in drug discovery.
At Kataba Therapeutics, we engineer tailor-made biologics that precisely engage disease-driving proteins, to modulate or inhibit pathogenic variants with unmatched specificity.
By leveraging advanced protein engineering techniques, we:
- Engage cryptic epitopes inaccessible to traditional biologics
- Identify functional bispecific configurations
- Develop active, conditional binders for highly selective therapies
We’re rewriting the rules of drug discovery, and unlocking an entirely new class of therapeutics – smaller, smarter, and built for impact.
Founder PROFILE
Eric Miller, PhD
Dr. Miller earned his PhD in Chemical Engineering from MIT in 2019 and has over a decade of experience in developing minimalist antibody mimetics. He specializes in agile protein engineering, applying efficient design principles and rapid iteration to accelerate therapeutic discovery. His work focuses on higher-order functional selection strategies, enabling the precise development of next-generation biologics.